Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3720-3730

  Joensuu, Heikki ^a   Holli, Kaija ^a   Heikkinen, Mirja ^a   Suonio, Eero ^a   Aro, Arja R ^a   Hietanen, Päivi ^a   Huovinen, Riikka ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; ETIDRONIC ACID; FLUOROURACIL; MITOMYCIN; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032423157     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3720     Document Type: Article

References (31)

1. Brincker H: Distant recurrence in breast cancer. Acta Oncol 27:729-732, 1988
2. Cold S, Jensen NV, Brincker H, et al: The influence of chemotherapy on survival after recurrence in breast cancer - a population-based study of patients treated in the 1950's, 1960's, and 1970's. Eur J Cancer 29A:1146-1152, 1993
3. Cooper RG: Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 10:15, 1969 (abstr)
4. Gundersen S, Kvinnsland S, Klepp O, et al: Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22:1431-1434, 1986
5. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9:305-312, 1991
6. Chlebowski RT, Irwin LE, Pugh RP, et al: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39:4503-4506, 1979
7. Canellos GP, Pocock SJ, Taylor SG III, et al: Combination chemotherapy for metastatic breast carcinoma. Cancer 38:1882-1886, 1976
8. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer. Cancer 38:13-20, 1976
9. Norris B, Pritchard K, James K, et al: A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: A National Cancer Institute of Canada study. Proc Am Soc Clin Oncol 15:98, 1996 (abstr)
10. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr)
11. Rubens RD, Knight RK, Hayward JL: Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32:730-736, 1975
12. Nemoto T, Rosner D, Diaz R, et al: Combination chemotherapy for metastatic breast cancer. Comparison of multiple drug therapy with 5-fluorouracil. Cytoxan and prednisone with Adriamycin or adrenalectomy. Cancer 41:2073-2077, 1978
13. Ahmann DL, Bisel HF, Eagan RT, et al: Controlled evaluation of Adriamycin (NSC-123127) in patients with dissseminated breast cancer. Cancer Chemother Rep 58:877-882, 1974
14. Chlebowski RT, Smalley RV, Weiner JM, et al: Combination versus sequential single agent chemotherapy in advanced breast cancer: Associations with metastatic sites and long-term survival. Br J Cancer 59:227-230, 1989
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. de Haes JCJM, van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 61:1034-1038, 1990
17. Radford JA, Knight RK, Rubens RD: Mitomycin C and vinblastine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 21:1475-1477, 1985
18. Godfrey TE: Mitomycin C in advanced breast cancer: An update. Semin Oncol 15:71-73, 1988
19. 2) in FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 8:155-162, 1997
20. Focan C, Andrien JM, Closon Mth, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
21. Ebbs SR, Sauders JA, Graham H, et al: A randomized trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol 28:887-892, 1989
22. Clemons M, Leahy M, Valle J, et al: Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur J Cancer 33:2183-2193, 1997
23. Dieras V, Marty M, Tubiana N, et al: Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22:33-39, 1995 (suppl 8)
24. Nabholtz JM, Thuerlimann B, Beswoda WR, et al: Taxotere improves survival over mitomycin C vinblastine (MV) in patients with metastatic breast cancer who have failed an anthracycline containing regimen: Final results of a phase III randomized trial. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr)
25. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two levels of Adriamycin in the primary treatment of disseminated breast carcinoma. Br J Cancer 56:471-473, 1987
26. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991
27. Creech RH, Catalano RB, Hopson RC: A comparison of standard dose Adriamycin and low dose Adriamycin as primary chemotherapy for metastatic breast cancer. Proc Am Assoc Cancer Res 21:142, 1980 (abstr)
28. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996
29. Hortobagyi GN, Bodey GP, Buzdar AY, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5:354-364, 1987
30. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose-intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 21:10-16, 1994 (suppl 1)
31. Fountzilas G, Athanassiades A, Giannakakis T, et al: A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 8:1213-1220, 1997